Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Interest & Investment Income (2022 - 2025)

Taysha Gene Therapies' Interest & Investment Income history spans 4 years, with the latest figure at $3.2 million for Q3 2025.

  • For Q3 2025, Interest & Investment Income rose 50.4% year-over-year to $3.2 million; the TTM value through Sep 2025 reached $8.1 million, up 12.47%, while the annual FY2024 figure was $6.9 million, 94.29% up from the prior year.
  • Interest & Investment Income for Q3 2025 was $3.2 million at Taysha Gene Therapies, up from $1.9 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.2 million in Q3 2025 and bottomed at $9000.0 in Q3 2022.
  • The 4-year median for Interest & Investment Income is $1.3 million (2025), against an average of $1.1 million.
  • The largest annual shift saw Interest & Investment Income skyrocketed 12222.22% in 2023 before it fell 21.68% in 2025.
  • A 4-year view of Interest & Investment Income shows it stood at $199000.0 in 2022, then skyrocketed by 865.33% to $1.9 million in 2023, then decreased by 11.5% to $1.7 million in 2024, then skyrocketed by 86.41% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Interest & Investment Income are $3.2 million (Q3 2025), $1.9 million (Q2 2025), and $1.3 million (Q1 2025).